Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1999-5-27
pubmed:abstractText
Excessive cyclo-oxygenase-2 (COX-2) induction may play a role in chronic neurological diseases characterized by inflammation and astrogliosis. We have previously identified an astroglial receptor for extracellular nucleotides, a P2Y receptor, whose stimulation leads to arachidonic acid (AA) release, followed, 3 days later, by morphological changes resembling reactive astrogliosis. Since COX-2 may be upregulated by AA metabolites, we assessed a possible role for COX-2 in P2Y receptor-mediated astrogliosis. A brief challenge of rat astrocytes with the ATP analogue alpha,beta-methylene ATP (alpha,beta(me)ATP) resulted, 24 h later, in significantly increased COX-2 expression. The selective COX-2 inhibitor NS-398 completely abolished alpha,beta(me)ATP-induced astrocytic activation. Constitutive astroglial COX-1 or COX-2 did not play any role in purine-induced reactive astrogliosis. PGE2, a main metabolite of COX-2, also induced astrocytic activation. These data suggest that a P2Y receptor mediates reactive astrogliosis via induction of COX-2. Antagonists selective for this receptor may counteract excessive COX-2 activation in both acute and chronic neurological diseases.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-1149797, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-2918318, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-7724657, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-8140262, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-8309563, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-8545546, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-8598929, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-8783630, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-8787135, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-8930343, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-9168834, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-9182946, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-9283705, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-9283706, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-9416670, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-9425266, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-9449430, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188963-9596581
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Triphosphate, http://linkedlifedata.com/resource/pubmed/chemical/Aspirin, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Dinoprostone, http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes, http://linkedlifedata.com/resource/pubmed/chemical/N-(2-cyclohexyloxy-4-nitrophenyl)met..., http://linkedlifedata.com/resource/pubmed/chemical/Nitrobenzenes, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin D2, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic P2, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/alpha,beta-methyleneadenosine...
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
126
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
563-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:10188963-Adenosine Triphosphate, pubmed-meshheading:10188963-Animals, pubmed-meshheading:10188963-Aspirin, pubmed-meshheading:10188963-Astrocytes, pubmed-meshheading:10188963-Cells, Cultured, pubmed-meshheading:10188963-Cyclooxygenase 2, pubmed-meshheading:10188963-Cyclooxygenase 2 Inhibitors, pubmed-meshheading:10188963-Cyclooxygenase Inhibitors, pubmed-meshheading:10188963-Dinoprostone, pubmed-meshheading:10188963-Dose-Response Relationship, Drug, pubmed-meshheading:10188963-Gliosis, pubmed-meshheading:10188963-Isoenzymes, pubmed-meshheading:10188963-Nitrobenzenes, pubmed-meshheading:10188963-Prostaglandin D2, pubmed-meshheading:10188963-Prostaglandin-Endoperoxide Synthases, pubmed-meshheading:10188963-Rats, pubmed-meshheading:10188963-Receptors, Purinergic P2, pubmed-meshheading:10188963-Sulfonamides, pubmed-meshheading:10188963-Time Factors
pubmed:year
1999
pubmed:articleTitle
Cyclo-oxygenase-2 mediates P2Y receptor-induced reactive astrogliosis.
pubmed:affiliation
Institute of Pharmacological Sciences, University of Milan, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't